Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.

Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica (2013) 1.17

Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia (2013) 0.92

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am J Hematol (2014) 0.86

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica (2015) 0.75

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. Haematologica (2014) 0.75

Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol (2012) 0.75

Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59

Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer (1997) 8.27

Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana. Nature (1998) 5.91

Sodium-driven potassium uptake by the plant potassium transporter HKT1 and mutations conferring salt tolerance. Science (1995) 5.52

Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12

Molecular recombination in T4 bacteriophage deoxyribonucleic acid. I. Tertiary structure of early replicative and recombining deoxyribonucleic acid. J Virol (1967) 3.96

Homeosis and intestinal tumours in Cdx2 mutant mice. Nature (1997) 3.68

Inhibition of an early event in the cell division cycle of Escherichia coli by FL1060, an amidinopenicillanic acid. J Bacteriol (1975) 3.49

Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46

Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg (1993) 3.45

Structural and mechanistic basis of immunity toward endonuclease colicins. Nat Struct Biol (1999) 3.37

A gene family of silicon transporters. Nature (1997) 3.19

Perspectives on the physiology and structure of inward-rectifying K+ channels in higher plants: biophysical implications for K+ uptake. Annu Rev Biophys Biomol Struct (1994) 3.16

Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol (2000) 3.10

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91

Polypeptide growth factors. Annu Rev Biochem (1984) 2.88

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83

Measurements of energetic particle radiation in transit to Mars on the Mars Science Laboratory. Science (2013) 2.83

Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet (2001) 2.80

Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet (1993) 2.64

Lipid- and temperature-dependent structural changes in Acholeplasma laidlawii cell membranes. Biochim Biophys Acta (1973) 2.59

stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol (1998) 2.58

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood (1999) 2.56

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50

Expression of Cdx-2 in the mouse embryo and placenta: possible role in patterning of the extra-embryonic membranes. Dev Dyn (1995) 2.43

The DNA sequence and biological annotation of human chromosome 1. Nature (2006) 2.42

Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J (1990) 2.42

General hospital services for attempted suicide patients: a survey in one region. Health Trends (1995) 2.38

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2006) 2.38

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24

The dissociation of discriminative and conditioned reinforcing functions of stimuli with changes in deprivation. J Exp Anal Behav (1968) 2.24

Complications and side effects of hyperbaric oxygen therapy. Aviat Space Environ Med (2000) 2.17

Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev (2004) 2.17

Safety of surfaces and equipment for children in playgrounds. Lancet (1997) 2.12

The triose phosphate-3-phosphoglycerate-phosphate translocator from spinach chloroplasts: nucleotide sequence of a full-length cDNA clone and import of the in vitro synthesized precursor protein into chloroplasts. EMBO J (1989) 2.10

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08

Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med (1998) 2.05

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol (2012) 2.03

Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection (2012) 2.02

Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer (1993) 2.01

Assortative interactions and social networks in fish. Oecologia (2005) 1.97

Rapid folding with and without populated intermediates in the homologous four-helix proteins Im7 and Im9. J Mol Biol (1999) 1.97

DNMT3A mutations in myeloproliferative neoplasms. Leukemia (2011) 1.95

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia (2012) 1.93

Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia (2009) 1.92

Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke (1997) 1.91

Food intolerance and the irritable bowel syndrome. Gut (1989) 1.88

Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.88

Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem (1995) 1.86

Protein-protein interactions in colicin E9 DNase-immunity protein complexes. 1. Diffusion-controlled association and femtomolar binding for the cognate complex. Biochemistry (1995) 1.85

European principles of haemophilia care. Haemophilia (2008) 1.84

Molecular characterization of a carbon transporter in plastids from heterotrophic tissues: the glucose 6-phosphate/phosphate antiporter. Plant Cell (1998) 1.82

Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene (1998) 1.81

Primary surgical repair of anterior vaginal prolapse: a randomised trial comparing anatomical and functional outcome between anterior colporrhaphy and trocar-guided transobturator anterior mesh. BJOG (2011) 1.80

Immunological study of carcinoembryonic antigen (CEA) and a related glycoprotein. Br J Cancer (1973) 1.78

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75

Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg (1994) 1.75

Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res (1997) 1.74

ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care (2005) 1.73

High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72

Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia (2006) 1.70

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol (2001) 1.70

B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet (2001) 1.70

Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg (1996) 1.69

11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood (1997) 1.69

Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol (2000) 1.68

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia (2004) 1.68

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68

Electrospun nanofiber scaffolds: engineering soft tissues. Biomed Mater (2008) 1.68

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol (2003) 1.66

ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia (2007) 1.64

Specificity in protein-protein interactions: the structural basis for dual recognition in endonuclease colicin-immunity protein complexes. J Mol Biol (2000) 1.64

Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand (2006) 1.63

Social phobia in spasmodic torticollis. J Neurol Neurosurg Psychiatry (2001) 1.62

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62